Molecular Partners’ Post

Exciting times at Abdera Therapeutics! The U.S. FDA has given the green light 🚦 to the Investigational New Drug (IND) application for ABD-147, a revolutionary Radiopharmaceutical treatment for small cell lung cancer (SCLC) and large cell neuroendocrine carcinoma (LCNEC). Abdera's innovative ROVEr™ platform, ABD-147 is a precision radiopharmaceutical poised to transform cancer treatment. This novel therapy targets DLL3 - a marker on aggressive neuroendocrine tumors, sparing normal cells. The gears are in motion to launch a Phase 1 clinical trial in late 2024. #FDA #Radiopharmaceuticals #Biotechnology #Neuroendorcinecarcinoma #Cancer #Oncology #SCLC #ClinicalDevelopment #CancerResearch #NuclearMedicine

🚀 Exciting News in the World of Antibody Drug Conjugates!🔬 🌟 Dive into the latest edition of ADC Digest for the first week of May 2024, where groundbreaking advancements are illuminating the field of Antibody Drug Conjugates! 💊 Pfizer and Genmab’s ADC Tivdak receive full FDA approval for recurrent or metastatic cervical cancer 💊 AstraZeneca, Daiichi tout Enhertu trial win in earlier, broader HER2-low breast cancer Stay tuned for more updates and breakthroughs in the realm of Antibody-Drug Conjugates! #ADC #MedicalInnovations #CancerResearch #approval #Innovation #ADCnews #CIScientists #Antibodydrugconjugate

#transcript John Celebi, the President and Chief Executive Officer of Sensei Biotherapeutics, emphasizes the need to develop better patient selection strategies and next-generation therapeutics for cancer patients. Through their Tumor Microenvironment-Activated Biologics platform (TMAb), Sensei develops conditionally active therapeutics designed to be active only within the low-pH tumor microenvironment.  Current pipeline candidates are designed to be active only within the low-pH tumor microenvironment and show potential to overcome the challenges of VISTA, a promising checkpoint target. #ImmunOncology #PatientSelection #Immunotherapy #Cancer #Tumors #ImmuneCheckpointTargets SenseiBio.com https://lnkd.in/gsYQyX4K

📰 #NSCLC | ASCO24: J&J's subQ Rybrevant matches efficacy, shrinks infusion time in Phase III trial "The PALOMA-3 trial, presented Friday at the American Society of Clinical Oncology (ASCO) annual meeting, is testing the SC formulation of J&J's EGFR/MET-targeting bispecific antibody in 418 patients with EGFR-mutated, advanced or metastatic non-small-cell lung cancer (NSCLC) and exon 19 deletion or L858R mutations [...]" https://hubs.ly/Q02zY4Bq0 FirstWord Pharma

Accelerate your oncology drug development journey with Physiomics plc! 🧪 Navigating the intricacies of developing great cancer drugs requires expertise and innovation. From initial discovery to clinical application, we're here to provide practical solutions that elevate your drug development success and address the real-world complexities of treating #cancer. Learn more: https://lnkd.in/e7rA8RCH #Cancer #DrugDevelopment #VirtualTumour #Immunotherapy #CancerDrugs #CancerSimulation #CombinationTherapies #QSP #MathematicalModelling #PKPD #MechanisticModelling #Oncology #ClinicalTrials #ResearchandDevelopment #CancerResearch #BioTech #StatisticalModelling #MachineLearning #Pharma #PYC

Will #oncologists add chemo to their use of AstraZeneca’s Tagrisso? To find out, we are launching a poll to physicians looking at the potential impact of Tagrisso plus chemotherapy regimen for the treatment of advanced EGFRm non-small-cell #lungcancer (NSCLC). Learn more here: https://lnkd.in/eD7kuxTe #AstraZeneca #cancer #NSCLC #oncology #pharmaceuticals #regulatoryaffairs

Delighted to announce the publication of our article 'Prognostic Biomarkers for Triple-Negative Breast Cancer: A Narrative Review' in the International Journal of Pharmaceutical Sciences. This work sheds light on the critical markers that could revolutionize the prognosis and treatment of triple-negative breast cancer. #BreastCancerAwareness #MedicalResearch #InnovationInHealthcare"

NX-1607, a First-in-Class Inhibitor of Casitas B-Lineage Lymphoma-b (CBL-B) for Immuno-Oncology with Frederick Cohen from Nurix Therapeutics. The E3 ubiquitin ligase CBL-B is expressed in multiple immune cell lineages and is a master regulator of immune response. NX-1607 is a molecule that glues CBL-B into an inactive conformation lowering the threshold for T cell activation. In cancer models, NX-1607 inhibits tumor growth when dosed orally. We present preclinical data on NX-1607, supporting its advancement to clinical testing, and pharmacokinetic-pharmacodynamic (PK-PD) data from the FIH trial (NCT05107674). https://lnkd.in/e8NAGvXe Save $150 with Discount code SPK150. #drugdiscoverychemistry

🧬✨ Case Study Highlight: Discovering the impact of next-generation sequencing (NGS) on treatment decisions in oncology. “What do cancer patients understand about next-generation sequencing?” This is the question an Inspire client wanted to answer. Using RWD on the Inspire platform, research uncovered how patients use NGS information to guide decisions. Highlights include: 📝 Most patients believe information from NGS determines their treatment 🩺 50% of respondents used NGS information to search for clinical trials and treatments Read the full case study at the link below and visit us at Booth 33168 to dive deeper into our findings! https://ow.ly/yZW350RY8Wq Want to schedule time with our team? https://lnkd.in/esvAu2YJ #ASCO24 #PrecisionMedicine #Oncology #NGS #PatientVoice

Read the full case study at the link below and visit us at #ASCO24 Booth 33168 to dive deeper into our findings!